Pulmonary Vascular Disease News

Few patients with primary pulmonary arterial hypertension were treated with exercise rehabilitation in the form of pulmonary or cardiac rehabilitation, according to data scheduled for presentation at the American Thoracic Society International Conference.

Healio Pulmonology has you covered. The Editors have compiled a list of popular articles posted on Healio Pulmonology in May.

Abiomed announced that the FDA issued an emergency use authorization for a temporary heart pump for patients with COVID-19 with right HF or decompensation including pulmonary embolism.

Thromboprophylaxis with low-molecular-weight heparin alone appeared noninferior to thromboprophylaxis combined with graduated compression stockings for individuals at moderate or high risk for venous thromboembolism after elective surgery, according to results of a randomized study published in BMJ.

Given the novelty of COVID-19 and a lack of scientific evidence, many clinicians treating critically ill patients with the disease, particularly those with acute respiratory distress syndrome, have been using conventional supportive care strategies and mechanical ventilation. Questions have emerged, however, about whether other treatments may also prove beneficial in this patient population.

Healio Pulmonology has you covered. The Editors have compiled a list of popular articles posted on Healio Pulmonology in April.

A case series published in Circulation by physicians at Lille University Hospital in France reported twice the prevalence of pulmonary embolism among patients with COVID-19 admitted to the ICU compared with patients admitted to the ICU the same time in 2019.

Among patients with pulmonary artery hypertension, intravascular ultrasound pulmonary artery denervation was associated with reductions in pulmonary vascular resistance and increases in 6-minute walk distance and daily activity, according to an early feasibility study published in JACC: Cardiovascular Interventions.

Patients treated with PCSK9 inhibitors had reduced risk for venous thromboembolism, especially if they had elevated lipoprotein(a), according to findings presented at the virtual American College of Cardiology Scientific Session.

The FDA has granted breakthrough therapy designation to sotatercept for treatment of pulmonary arterial hypertension, according to a press release from Acceleron Pharma.